Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)

被引:167
作者
Lu, Jie [1 ]
Rohani, Sohrab [1 ]
机构
[1] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada
关键词
Crystallization; polymorphism; pseudopolymorphism; active pharmaceutical ingredients (APIs); discovery; control; SOLID-STATE NMR; CRYSTAL-STRUCTURE PREDICTION; LASER-INDUCED NUCLEATION; METASTABLE POLYMORPH; MOLECULAR-CRYSTALS; STABLE POLYMORPH; CO-CRYSTALS; PHYSICOCHEMICAL PROPERTIES; DISSOLUTION RATE; VENLAFAXINE HYDROCHLORIDE;
D O I
10.2174/092986709787549299
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Active pharmaceutical ingredients (APIs), frequently delivered to the patient in the solid-state as part of an approved dosage form, can exist in such diverse solid forms as polymorphs, pseudopolymorphs, salts, co-crystals and amorphous solids. Various solid forms often display different mechanical, thermal, physical and chemical properties that can remarkably influence the bioavailability, hygroscopicity, stability and other performance characteristics of the drug. Hence, a thorough understanding of the relationship between the particular solid form of an active pharmaceutical ingredient (API) and its functional properties is important in selecting the most suitable form of the API for development into a drug product. In past decades, there have been significant efforts on the discovery, selection and control of the solid forms of APIs and bulk drugs. This contribution discusses the thermodynamics and kinetics of polymorphic systems, the characterization of polymorphs, and the transformation between polymorphs. The major techniques for polymorph discovery and control developed in the past years are discussed as well.
引用
收藏
页码:884 / 905
页数:22
相关论文
共 223 条
[1]   Cocrystal or salt:: Does it really matter? [J].
Aakeroy, Christer B. ;
Fasulo, Meg E. ;
Desper, John .
MOLECULAR PHARMACEUTICS, 2007, 4 (03) :317-322
[2]   DEHYDRATION OF THEOPHYLLINE MONOHYDRATE POWDER - EFFECTS OF PARTICLE-SIZE AND SAMPLE WEIGHT [J].
AGBADA, CO ;
YORK, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1994, 106 (01) :33-40
[3]   Water dynamics in channel hydrates investigated using H/D exchange [J].
Ahlqvist, MUA ;
Taylor, LS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 241 (02) :253-261
[4]   High-throughput surveys of crystal form diversity of highly polymorphic pharmaceutical compounds [J].
Almarsson, Ö ;
Hickey, MB ;
Peterson, ML ;
Morissette, SL ;
Soukasene, S ;
McNulty, C ;
Tawa, M ;
MacPhee, JM ;
Remenar, JF .
CRYSTAL GROWTH & DESIGN, 2003, 3 (06) :927-933
[5]   Solid state characterization of olanzapine polymorphs using vibrational spectroscopy [J].
Ayala, A. P. ;
Siesler, H. W. ;
Boese, R. ;
Hoffmann, G. G. ;
Polla, G. I. ;
Vega, D. R. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 326 (1-2) :69-79
[6]   Indomethacin-saccharin cocrystal:: Design, synthesis and preliminary pharmaceutical characterization [J].
Basavoju, Srinivas ;
Bostrom, Dan ;
Velaga, Sitaram P. .
PHARMACEUTICAL RESEARCH, 2008, 25 (03) :530-541
[7]   Ritonavir: An extraordinary example of conformational polymorphism [J].
Bauer, J ;
Spanton, S ;
Henry, R ;
Quick, J ;
Dziki, W ;
Porter, W ;
Morris, J .
PHARMACEUTICAL RESEARCH, 2001, 18 (06) :859-866
[8]   Polymorphic transitions of cimetidine during manufacture of solid dosage forms [J].
BauerBrandl, A .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 140 (02) :195-206
[9]  
Bechtloff B, 2001, CRYST RES TECHNOL, V36, P1315, DOI 10.1002/1521-4079(200112)36:12<1315::AID-CRAT1315>3.0.CO
[10]  
2-R